Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 36B-42B

  Vega, Gloria Lena ^a   Grundy, Scott M ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

CONFERENCE PAPER; DRUG ACTIVITY; DRUG MIXTURE; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0032567905     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00036-8     Document Type: Conference Paper

References (26)

1. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24-33.
2. Endo A. The discovery and development of HMG CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582.
3. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
5. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole triglyceride, Brown L, Warnica JW, Arnold JMO, Wun C-C, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
6. Genest JJ Jr, Martin-Munley SS, McNamara JR, Ordovas JM, Jenner J, Myers RH, Silberman SR, Wilson PW, Salem DN, Schaefer EJ. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation 1992;85:2025-2033.
7. Vega GL, Denke MA, Grundy SM. Metabolic basis of primary hypercholesterolemia. Circulation 1991;84:118-128.
8. Havel RJ. Triglyceride-rich lipoproteins and atherosclerosis - new perspectives. Am J Clin Nutr 1994;59:795-799.
9. Vega GL, East C, Grundy SM. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B. Atherosclerosis 1988;70:131-143.
10. Vega GL, Grundy SM. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. JAMA 1990;264:2759-2763.
11. Vega GL, Grundy SM. Management of primary mixed hyperlipidemia with lovastatin. Arch Intern Med 1990;150:1313-1319.
12. Vega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism. Kidney Int 1988;33:1160-1168.
13. Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins. JAMA 1985;253:2398-2403.
14. Vega GL, Toto RD, Grundy SM. Metabolism of low density lipoproteins in nephrotic dyslipidemia: comparison hypercholesterolemia alone and combined hyperlipidemia. Kidney Int 1995;47:579-586.
15. Janus ED, Nicoll A, Wootton R, Turner PR, Magill PJ, Lewis B. Quantitative studies of very low density lipoprotein in normal controls and primary hyperlipidemic states and the role of direct secretion of low density lipoprotein in heterozygous familial hypercholesterolemia. Eur J Clin Invest 1980;10:149-159.
16. Kissebah AH, Alfarsi S, Evans DJ. Low density lipoprotein metabolism in familial combined hyperlipidemia: mechanism of the multiple lipoprotein phenotypic expression. Arteriosclerosis 1984;4:614-624.
17. Chait A, Foster DM, Albers JJ, Failor RA, Brunzell JD. Low density lipoprotein metabolism in familial combined hyperlipidemia and familial hypercholesterolemia: kinetic analysis using an integrated model. (Abstr.) Metabolism 1986;35:697.
18. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate density lipoproteins with smoking and coronary heart disease. Circulation 1987;75:124-130.
19. Havel RJ. The formation of LDL: mechanisms and regulation. J Lipid Res 1984;25:1570-1576.
20. Tato F, Vega GL, Grundy SM. Determinants of plasma HDL cholesterol in hypertriglyceridemic patients: role of cholesterol ester transfer protein and lecithin cholesterol acyl transferase. Arterioscler Thromb Vasc Biol 1997;17:56-63.
21. Mostaza JM, Vega GL, Snell P, Grundy SM. Abnormal metabolism of free fatty acids in hypertriglyceridemic man: apparent insulin resistance of adipose tissue. J Intern Med March 1998, in press.
22. Knudsen P, Eriksson J, Lahdenpera S, Kahri J, Groop L, Taskinen MR. Changes of lipolytic enzymes cluster with insulin resistance syndrome. Diabetologia 1995;38:344-350.
23. Dammerman M, Sandkuijl LA, Halaas JL, Chung W, Breslow JL. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc Natl Acad Sci USA 1993;90:4562-4566.
24. Katzel LI, Coon PJ, Busby MJ, Gottlieb SO, Krauss RM, Goldberg AP. Reduced HDL2 cholesterol subspecies and elevated postheparin hepatic lipase activity in older men with abdominal obesity and asymptomatic myocardial ischemia. Arterioscler Thromb 1992;12:814-823.
25. Uauy R, Vega GL, Grundy SM, Bilheimer DM. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. J Pediatr 1988;113:387-392.
26. Mostaza JM, Schulz I, Vega GL, Grundy SM. Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. Am J Cardiol 1997;79:1298-1301.